Given the robust effects of EGFR gene amplification and EGFRvIII on GBM progression, it would be reasonable to assume that EGFR-targeting therapeutics would be effective in treating GBM; however, although temporary responses may be observed, tumors typically escape from control (Voelzke et al., 2008). Here, EGFR is linked to glioblastoma.